Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Evolution of B-Cell Malignancy Therapy and Treatment Resistance: Where Are...
share announcement

Evolution of B-Cell Malignancy Therapy and Treatment Resistance: Where Are We Headed? (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 3978

Special Issue Editors

Prof. Dr. Jianguo Tao

E-Mail Website
Guest Editor
Department of Pathology, University of Virginia Medical Center, Charlottesville, VA 22903, USA
Interests: B-cell malignancy; drug resistance; novel therapy
Special Issues, Collections and Topics in MDPI journals
Dr. Jeffrey W. Craig

E-Mail Website
Guest Editor
Department of Pathology, University of Virginia Medical Center, Charlottesville, VA 22908, USA
Interests: lymphoid neoplasms
Prof. Dr. Michael E. Williams

E-Mail Website
Guest Editor
Hematology/Oncology Division, University of Virginia Cancer Center, Charlottesville, VA 22908, USA
Interests: chronic lymphocytic leukemia; mantle cell lymphoma; non-Hodgkin lymphoma

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the Special Issue titled “Evolution of B-Cell Malignancy Therapy and Treatment Resistance: Where Are We Headed?” https://www.mdpi.com/journal/cancers/special_issues/6GH8RRC7FR.

Advances in our understanding of B-cell neoplasm biology, genetics, and immunology have allowed for the identification of new therapeutic targets and the emergence of bispecific antibodies, CAR T-cell therapies, and novel small-molecule inhibitors. However, outcomes for relapsed and/or refractory lymphoma, myeloma, and CLL with therapy resistance remain inadequate for most patients. Thus, an unmet need exists for the development of novel and effective therapeutic strategies based on lymphoma biology and resistance mechanisms. In this Special Issue, we will focus on the changing therapeutic landscape of B-cell malignancies, from chemoimmunotherapy to targeted agents and immunotherapeutic approaches, and the evolutionary trajectories of treatment resistance. We will provide perspectives and evidence-based rationale for novel combinatorial strategies to synergistically and reciprocally overcome treatment resistance, enhance clinical efficacy, and improve patient outcomes.

Prof. Dr. Jianguo Tao
Dr. Jeffrey W. Craig
Prof. Dr. Michael E. Williams
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • B-cell malignancy
  • drug resistance
  • novel therapy
  • TME
  • chemoimmunotherapy
  • targeted agents
  • immunotherapeutic approaches

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 1539 KB  
Review
Transcriptional Condensates: Epigenetic Reprogramming and Therapeutic Targets in Hematologic Malignancies
by Kevin Qiu, Qing Yin, Chongzhi Zang and Jianguo Tao
Cancers 2025, 17(19), 3148; https://doi.org/10.3390/cancers17193148 (registering DOI) - 27 Sep 2025
Abstract
Transcription is a core hallmark of cancer, wherein many different proteins assemble at specific sites in the nucleus and act in concert to transcribe functionally relevant genes. Central to this process are transcription factors that bind to their cognate DNA motifs on enhancers [...] Read more.
Transcription is a core hallmark of cancer, wherein many different proteins assemble at specific sites in the nucleus and act in concert to transcribe functionally relevant genes. Central to this process are transcription factors that bind to their cognate DNA motifs on enhancers and super-enhancers to recruit cofactors, coactivators, and epigenetic modifiers, thereby inducing or repressing gene expression. Super-enhancers drive oncogenic transcription, to which cancer cells become highly addicted and confer tumor dependencies on super-enhancer-driven transcription machinery. Transcriptional condensates (TCs) are nuclear membrane-less assemblies of DNA-binding transcription factors, transcription co-activators, and the transcriptional machinery (such as RNA polymerases, non-coding RNAs) formed through liquid–liquid phase separation (LLPS). The function of transcriptionally active oncogenic proteins and their interplay with nucleic acids are carried out within these biomolecular condensates, allowing them to spatiotemporally regulate oncogene expression and lead to the induction and maintenance of cancer. With this growing understanding, specific inhibitors and strategies targeting TC assembly and activation should be considered promising therapeutic opportunities for treating various tumors, including hematological malignancies. Full article
(This article belongs to the Special Issue Evolution of B-Cell Malignancy Therapy and Treatment Resistance: Where Are We Headed? (2nd Edition))
►▼ Show Figures

Figure 1

21 pages, 6387 KB  
Review
The Landscape of Primary Central Nervous System Lymphoma (PCNSL): Clinicopathologic and Genomic Characteristics and Therapeutic Perspectives
by Huijuan Jiang and Lin Nong
Cancers 2025, 17(17), 2909; https://doi.org/10.3390/cancers17172909 - 4 Sep 2025
Viewed by 1054
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare extra-nodal non-Hodgkin lymphoma confined to the central nervous system. The cancer biology of PCNSL remains incomplete and is often associated with genetic aberrations with abnormal signaling pathways, cell differentiation, regulation of epigenetic modification, and [...] Read more.
Primary central nervous system lymphoma (PCNSL) is a rare extra-nodal non-Hodgkin lymphoma confined to the central nervous system. The cancer biology of PCNSL remains incomplete and is often associated with genetic aberrations with abnormal signaling pathways, cell differentiation, regulation of epigenetic modification, and the tumor microenvironment. Stereotactic brain biopsy remains the gold standard for the diagnosis of PCNSL. For patients ill-suited for biopsy, MYD88 and IL-10 may be important biomarkers to diagnose PCNSL. High-dose methotrexate-based polychemotherapy is currently the standard induction treatment for PCNSL, followed by consolidation treatments including autologous stem cell transplant and whole-brain radiotherapy. Some studies suggest that low-dose lenalidomide is recommended as a maintenance therapy for PCNSL. Currently, relapse rates of PCNSL range from 25 to 50% with poor prognosis. Insight research is necessary to identify novel targeted treatments to improve outcomes in relapsed/refractory disease, such as immunomodulatory drugs, immune checkpoint inhibitors, signaling pathway inhibitors, and chimeric antigen receptor T-cell therapy. Full article
(This article belongs to the Special Issue Evolution of B-Cell Malignancy Therapy and Treatment Resistance: Where Are We Headed? (2nd Edition))
►▼ Show Figures

Figure 1

12 pages, 415 KB  
Review
Diffuse Large B-Cell Lymphoma in the Older and Frail Patient
by Emily C. Ayers and Sonali M. Smith
Cancers 2025, 17(5), 885; https://doi.org/10.3390/cancers17050885 - 5 Mar 2025
Viewed by 2553
Abstract
Outcomes in older, unfit, and frail patients with diffuse large B-cell lymphoma (DLBCL) are inferior compared to younger and fit patients. Despite tremendous progress in the treatment landscape of DLBCL, few clinical trials have focused specifically on this high-risk patient population. This review [...] Read more.
Outcomes in older, unfit, and frail patients with diffuse large B-cell lymphoma (DLBCL) are inferior compared to younger and fit patients. Despite tremendous progress in the treatment landscape of DLBCL, few clinical trials have focused specifically on this high-risk patient population. This review focuses on the pathophysiology unique to the older patient with DLBCL, as well as the evidence behind current treatment approaches. This article also aims to highlight emerging prognostic tools and novel treatment strategies that may improve the outcomes in this patient cohort in the future. Full article
(This article belongs to the Special Issue Evolution of B-Cell Malignancy Therapy and Treatment Resistance: Where Are We Headed? (2nd Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop